Inflammation, insulin resistance, and obesity

被引：103

作者：

Ferroni P. ^{[1
]}

Basili S. ^{[1
]}

Falco A. ^{[1
]}

Davì G. ^{[1
]}

机构：

[1] Center of Excellence on Aging, 66013 Chieti, Via colle dell'Ara

来源：

Current Atherosclerosis Reports | 2004年 / 6卷 / 6期

关键词：

Obesity; Insulin Resistance; Metabolic Syndrome; Visceral Obesity; Insulin Resistance Syndrome;

D O I：

10.1007/s11883-004-0082-x

中图分类号：

学科分类号：

摘要：

Obesity, in particular visceral obesity, has strong associations with cardiovascular disease and is related to many factors that are constituents of the metabolic syndrome. Increasing evidence suggests that features of the metabolic syndrome, including visceral obesity, are associated with a low-grade inflammatory state. Indeed, visceral fat is a source of several molecules, such as leptin, adiponectin, tumor necrosis factor-α, and interleukin 6, that are collectively called adipokines. All of them may induce a proinflammatory state and oxidative damage, leading to initiation and progression of atherosclerosis. Reduced-energy diets might represent an effective and healthful approach for long-term weight loss in patients with metabolic syndrome by reducing the underlying inflammatory condition. Copyright © 2004 by Current Science Inc.

引用

页码：424 / 431

页数：7

共 50 条

[11]

Srinivasan S.R., Bao W., Wattigney W.A., Berenson G.S., Adolescent overweight is associated with adult overweight and related multiple cardiovascular risk factors: The Bogalusa heart study, Metabolism, 45, pp. 235-240, (1996)

[12]

Wright C.M., Parker L., Lamont D., Craft A.W., Implications of childhood obesity for adult health: Findings from thousand families cohort study, BMJ, 323, pp. 1280-1284, (2001)

[13]

Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report, Circulation, 106, pp. 3143-3421, (2002)

[14]

Marchesini G., Forlani G., Cerrelli F., Et al., WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes, Diabetes Med., 21, pp. 383-387, (2004)

[15]

Einhorn D., Reaven G.M., Cobin R.H., Et al., American College of Endocrinology position statement on the insulin resistance syndrome, Endocr. Pract., 9, pp. 237-252, (2003)

[16]

Grundy S.M., Brewer H.B., Cleeman J.I., Et al., Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition, Circulation, 109, pp. 433-438, (2004)

[17]

Steppan C.M., Lazar M.A., The current biology of resistin, J. Intern. Med., 255, pp. 439-447, (2004)

[18]

Benoit S.C., Clegg D.J., Seeley R.J., Woods S.C., Insulin and leptin as adiposity signals, Recent Prog. Horm. Res., 59, pp. 67-85, (2004)

[19]

Yamauchi T., Kamon J., Waki H., Et al., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity, Nat. Med., 7, pp. 941-946, (2001)

[20]

Yang W.S., Lee W.J., Funahashi T., Et al., Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin, J. Clin. Endocrinol. Metab., 86, pp. 3815-3819, (2001)

← 1 2 3 4 5 →